Advertisement
Cardiva also announced that Mr. Rick Anderson, a Managing Director withPTV Sciences will join Cardiva's Board of Directors. Prior to PTV Sciences,Mr. Anderson served as Company Group Chairman, Johnson & Johnson, andWorldwide Franchise Chairman, Cordis Corporation. He was a key architectbehind the launch of the world's first drug-eluting stent the CYPHER(R)Sirolimus-eluting Coronary Stent.
Advertisement
"We are delighted that PTV Sciences has joined with Cardiva's currentinvestors to finance the expansion of our direct sales force in the U.S.,"said Augustine Lien, Chairman and CEO. "We now have the resources toaggressively expand our customer base. We are also extremely pleased thatRick Anderson is joining our Board of Directors as his experience is ideallysuited to assist Cardiva's expansion in the U.S. cardiology market."
"We are extremely excited about Cardiva's growth prospects," commentedRick Anderson. "Cardiva represents an outstanding opportunity to improvepatient care by allowing patients to be discharged from the hospital fasterwithout the complications usually associated with vascular closure devices,especially in interventional cardiology."
About Cardiva Medical, Inc.
Founded in July 2002, and headquartered in Mountain View, Calif., CardivaMedical, Inc. is a privately held medical device company focused on developingand commercializing devices which close the vascular access site withunsurpassed safety and ease-of-use. Cardiva's first product, the BoomerangWire System, was approved in EU countries and in the U.S. in 2004. Cardiva'ssecond-generation product, the Boomerang Catalyst System, was approved inMarch 2007 and launched in July 2007. The enhanced Boomerang Catalyst, tradenamed as "Boomerang Catalyst II System" received 510(K) clearance in September2007 and launched in January 2008. Cardiva was selected by Frost & Sullivanas the recipient of the 2006 Frost & Sullivan Award for EntrepreneurialCompany in the U.S. angioplasty and vascular closure devices market. Foradditional information about Cardiva please see our website athttp://www.cardivamedical.com.
Certain statements in this press release are forward-looking within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements may be identified by the use of forward-looking words such as"anticipate," "believe," "forecast," "estimated" and "intend," among others.These forward-looking statements are based on Cardiva's current expectationsand actual results could differ materially. Cardiva does not undertake anobligation to update or revise any forward-looking statement.
Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registeredtrademarks of Cardiva Medical, Inc.Media Contact: Glenn Foy, President Cardiva Medical, Inc. Phone: 650.964.8900, x 215 Fax: 650.964.8911 [email protected]
SOURCE Cardiva Medical, Inc.
